Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 2208 results found since Jan 2013.
Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study
We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phospha...
Source: Neoplasma - July 27, 2023 Category: Cancer & Oncology Authors: Tomislav Omr čen Davor Eterovi ć Tea Jozi ć Eduard Vrdoljak Source Type: research
